



University of Dundee

Structured cost analysis of robotic TME resection for rectal cancer

Morelli, Luca; Di Franco, Gregorio; Lorenzoni, Valentina; Guadagni, Simone; Palmeri, Matteo; Furbetta, Niccolò

Published in:
Surgical Endoscopy

DOI:
[10.1007/s00464-018-6465-9](https://doi.org/10.1007/s00464-018-6465-9)

Publication date:
2018

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Morelli, L., Di Franco, G., Lorenzoni, V., Guadagni, S., Palmeri, M., Furbetta, N., ... Cuschieri, A. (2018). Structured cost analysis of robotic TME resection for rectal cancer: a comparison between the da Vinci Si and Xi in a single surgeon's experience. *Surgical Endoscopy*. <https://doi.org/10.1007/s00464-018-6465-9>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Structured cost analysis of robotic TME resection for rectal cancer: a comparison between the da Vinci Si and Xi in a single surgeon's experience

Running Head: Cost-comparison of Si and Xi in rectal cancer

Luca Morelli^{1,2}, MD, FACS; Gregorio Di Franco¹, MD; Valentina Lorenzoni³, PhD; Simone Guadagni¹, MD; Matteo Palmeri¹, MD; Niccolò Furbetta¹, MD; Desirée Gianardi¹, MD; Matteo Bianchini¹, MD; Giovanni Caprili¹, MD; Franco Mosca², MD, FACS; Giuseppe Turchetti³, PhD; Alfred Cuschieri⁴, MD, FRCS, FACS (Hon).

¹General Surgery, Department of Surgery, Translational and New Technologies, University of Pisa, Pisa, Italy

²EndoCAS (Center for Computer Assisted Surgery), University of Pisa, Pisa, Italy

³Institute of Management, Scuola Superiore Sant'Anna, Pisa, Italy

⁴Institute for Medical Science and Technology, University of Dundee, Dundee, Scotland, UK

Corresponding author:

Luca Morelli, MD, FACS

General Surgery, Department of Surgery, Translational and New Technologies, University of Pisa, Pisa, Italy

Via Paradisa 2, 56124 Pisa, Italy

Phone: +39-050-996930

Fax : +39-050-996985

Email : luca.morelli@unipi.it

Manuscript type: Original Article

Word count of entire article: 4522

Tables: 6

Figure: 1

The authors declare that no funding support was received for this study.

Background

Robotic-assisted surgery by the da Vinci Si appears to benefit rectal cancer surgery in selected patients, but still has some limitations, one of which is its high costs. Preliminary studies have indicated that the use of the new da Vinci Xi provides some added advantages, but their impact on cost is unknown. The aim of the present study is to compare surgical outcomes and costs of rectal cancer resection by the two platforms, in a single surgeon's experience.

Methods

From April 2010 to April 2017, 90 robotic rectal resections were performed, with either the da Vinci Si (Si-RobTME) or the da Vinci Xi (Xi-RobTME). Based on CUSUM analysis, two comparable groups of 40 consecutive Si-RobTME and 40 consecutive Xi-RobTME were obtained from the prospectively collected database and used for the present retrospective comparative study. Data costs were analysed based on the level of experience on the proficiency-gain curve (p-g-curve) by the surgeon with each platform.

Results

In both groups, two homogeneous phases of the p-g-curve were identified: Si1 and Xi1: cases 1–19, Si2 and Xi2: cases 20–40. A significantly higher number of full RAS operations was achieved in the Xi-RobTME group ($p < 0.001$). A statistically significant reduction in operating time (OT) during Si2 and Xi2 phase was observed ($p < 0.001$), accompanied by reduced overall variable costs (OVC), personnel costs (PC) and consumable costs (CC) ($p < 0.001$). All costs were lower in the Xi2 phase compared to Si2 phase: OT 265 vs. 290 min ($p = 0.052$); OVC 7983 vs. 10231.9 ($p = 0.009$); PC 1151.6 vs. 1260.2 ($p = 0.052$), CC 3464.4 vs. 3869.7 ($p < 0.001$).

Conclusions

Our experience confirms a significant reduction of costs with increasing surgeon's experience with both platforms. However, the economic gain was higher with the Xi with shorter OT, reduced PC and CC, in addition to a significantly larger number of cases performed by the fully robotic approach.

Key words

Robotic surgery, TME, rectal cancer, structured costs analysis, da Vinci Xi, da Vinci Si

INTRODUCTION

Robotic-assisted surgery (RAS) was introduced specifically to overcome the kinematic restrictions imposed on the operating surgeon by conventional laparoscopic surgery. RAS by the da Vinci Surgical system appears to benefit rectal cancer surgery, which in some early series included reduced conversion rates, reduced operative blood loss, greater residual mesorectal fascial integrity rate following pelvic dissection, shorter proficiency-gain curve (p-g-curve) and excellent functional results compared with the reported experience by the manual direct laparoscopic approach [1-8]. Nevertheless, even if not all these findings have been reported by the ROLARR trial [9] and by recent meta-analysis [10-12], potential advantages were confirmed in selected patients. However, the higher costs of RAS with the da Vinci remain a critical issue, and have prevented its widespread adoption. Additionally, there are other limitations to RAS by the da Vinci Si platform, including the limited flexibility for complete robotic multi-quadrant operations, imposing technical difficulty in achieving complete mobilization of splenic flexure. Furthermore, if changes in the position of the robot and/or the patient are needed, the robotic system must be undocked to enable safe reposition of the entire platform and re-docking or, alternatively, the surgeon must use a hybrid laparoscopic/robotic approach. The introduction of the new da Vinci Xi platform and its subsequent added use of the da Vinci Table Motion (dVTM) has overcome these limitations. Preliminary studies have indicated that the use of the new da Vinci Xi with the dVTM is associated with a shorter operative time, reduced docking time, and higher full robotic resection rates compared to the previous da Vinci Si [13-21]. The possible impact of these advantages of da Vinci Xi on costs is unknown. Despite several published studies regarding clinical and surgical benefits of robot-assisted colorectal surgery since the introduction of da Vinci Surgical System, to date few studies have reported a structured cost analysis, and none have analysed the possible differences in costs between da Vinci Si and new da Vinci Xi. The aim of this study is to compare surgical parameters and costs of robotic surgery for rectal cancer with the use of da Vinci Si and Xi surgical platforms.

MATERIALS AND METHODS

From April 2010 to April 2017, 90 robotic rectal resections were performed at the General Surgery Unit, University of Pisa, with the da Vinci Si (Si-RobTME) until December 2014, or with the da Vinci Xi (Xi-RobTME) since January 2015.

All the procedures were performed by a single surgeon previously experienced in rectal cancer surgery (>100 cases), with manual laparoscopic surgery (>100 cases), and who started his robotic experience with da Vinci Si in November 2009.

For the present study, data on patient outcomes, surgical procedures, and postoperative course were retrieved from a prospectively collected institutional dedicated database. The preoperative work-up included colonoscopy with biopsy, abdominal and trans-rectal ultrasonography, chest radiography,

abdomen and pelvic CT scan, and/or magnetic resonance imaging. Patients with clinical stage I cancer (T1-2, N0, M0) were referred for prompt surgical treatment. Patients with clinical stage II–III cancer with T3 and/or N-positive received neoadjuvant chemoradiation (continuous 5-FU infusion/ RT) followed by surgical resection within 8 weeks. T4 lesions were operated through an open approach and excluded from the study as were patients with clinical stage IV cancer (metastatic disease). Obesity (BMI >30 kg/m²) or previous abdominal or pelvic surgical procedures were not considered contraindication. An anterior resection of the rectum (ARR) was used for lesions with caudal margin located at least 3 cm above the dentate line. Intersphincteric resection (ISR) with direct manual colo-anal anastomosis was considered for lesions located between 3 and 0.5 cm above the dentate line, while lesions located less than 0.5 cm above the dentate line or with direct sphincter invasion, underwent an abdominoperineal resection (APR). A diverting ileostomy was performed in all ARR and ISR patients. The clinical variables included patient demographics, the American Society of Anaesthesiologists (ASA) scores, body mass index (BMI), neoadjuvant treatment and distance of the tumour from the anal verge were. The perioperative data were operating time (OT), docking time, the use of hybrid or full-robotic approach, and conversion to open or hand-assisted laparoscopic surgery (HALS). Postoperative data included length of stay and postoperative complication according to the Clavien–Dindo classification [22].

Cost data were obtained from the accounting department of the hospital and added to our institutional prospectively collected database. Costs were expressed in euros and referred to year 2016. Economic data were collected from the accounting department of the hospital. Because the study consisted of a comparison between two successive generations of the same robotic platform, we excluded from the analysis fixed costs (purchase and maintenance). In addition, stapler's costs were excluded because since the introduction of the endo-wristed staplers, they are now available for both systems, they were not available at the time our Si interventions were performed, and so inclusion of these costs in the analysis would have introduced a bias. In fact, for valid representation of consumable costs in current practice, robotic EndoWrist staplers should have been considered for both Si and Xi interventions, and hence do not have any impact on relative costs between the two platforms.

Overall variable costs (OVC) included items related to disposable instruments (consumable costs, CC), operating room personnel (personnel costs, PC), and length of stay (hospital stay costs, HC). Details of resources use and related costs are reported in Appendix (Table A1-A3).

Considering OT as an indicator of the proficiency-gain process, the CUSUM method [23] was used to analyse the p-g-curve for the two da Vinci systems. This method comprises running the total of the differences between the individual data points and the mean of all data points. First, the cases were ordered chronologically, from the earliest to the last date of surgery. The value of CUSUM operative time (CUSUMOT) of the first case was then obtained as the difference between the OT for the first case and the mean OT for all the cases (mOT). The CUSUMOT of the second case was the CUSUMOT of the

previous case added to the difference between the OT of the second case and mOT. The same procedure was repeated for each of the patients except the last one, which was marked as 0.

Based on CUSUM analysis, two comparable groups of 40 consecutive Si-RobTME and 40 consecutive Xi-RobTME were identified.

For the present study, clinical and costs data of these two groups were analysed and compared against the device specific robotic p-g-curve. To compare the variation of costs with the experience we also matched costs of each phase of the p-g-curve of the two groups.

The study was approved by Institutional review board. All patients received an extensive explanation of the procedure and provided informed consent.

Surgery

Surgical technique

For the Si-RobTME group, we used a single docking full robotic or hybrid technique, based on patient characteristics and intra-operative findings. Main criteria for the hybrid approach included difficulties in exposure of inferior mesenteric vein or splenic flexure; encroachment of the operative field by small bowel loops, visceral obesity and need of multiple changes of table position.

The patients were placed in a modified lithotomy position with a 30° Trendelenburg and a tilt to the right side. In the full robotic technique, a 12mm optical trocar for the camera was inserted 3 cm to the right and lateral to the umbilicus. An 8-mm trocar for the robotic arm was placed under direct vision at the point of intersection between the mid-clavicular line and the line between the umbilicus and the anterior superior iliac spines on the right side. The other two robotic trocars were inserted in the epigastric region, one on the right either side of the falciform ligament. Another 12mm trocar in the right flank was inserted for use by the assistant surgeon. In the hybrid technique, the first part of the operation (inferior mesenteric vessel ligation, left colon and splenic flexure mobilization) was carried out laparoscopically. The trocar for the camera was in the same position as in the full robotic technique, the two operative trocars were epigastric (8mm) and suprapubic (12 mm), respectively; an 8mm robotic trocar was placed in the left flank.

The choice for using a hybrid technique was made after placement of the optical trocar and the suprapubic trocar to expose and the evaluate quality of the operative field obtained with changes in the position of the operating table, being made as required. For the robotic step of the intervention (the TME), the cart was positioned to the patient's left side, along an imaginary line between the anterior superior iliac spine and the umbilical scar, at a 60° angle. During this step, the surgeon inserted the 8mm trocar inside the 12mm one (trocar in trocar) and another 12mm trocar was placed in the right flank for the use by the assistant.

In the Xi-RobTME group, patients were placed in a modified lithotomy position with a 30° Trendelenburg and a tilt to the right side. The first 8mm robotic trocar was placed in the umbilical region, along the right pararectal line. Four trocars were then inserted under vision in an oblique fashion following the classic universal port placement guidelines provided by Intuitive Surgical for 'left lower' abdominal procedures that provides for positioning an 8mm port in the right iliac fossa, a 12mm assistant's trocar in the right flank and two 8mm robotic ports in the periumbilical region and the left hypochondriac space, respectively. However, as previously reported [16-18], we prefer to locate all trocars by 2–5 cm to the right side, to enhance the workspace and facilitate the approach to the splenic flexure with the fourth arm. 'Patient-left' was the selected approach, and the surgical cart was driven to position the green laser crosshairs on the initial endoscope port. After docking, the scope was pointed at the inferior mesenteric pedicle of the sigmoid colon, and function 'targeting' was performed. The boom was then rotated in a clockwise direction to ensure the optimal configuration for dividing the inferior mesenteric pedicles and mobilizing the left colon up to the splenic flexure. In our initial experience, we performed a new targeting down to the pelvis with a consequent double docking. However, with increasing experience in performing TME we changed only the targeted anatomical site of the camera from the left side to the pelvis and changed the arm direction and the FLEX of each arm without the necessity to undock the robotic arms and a consequent second docking. The dVTM was used when necessary to obtain the optimal exposure of the operative field.

The colon was exteriorized through a Pfannenstiel suprapubic mini-laparotomy and prepared for the anastomosis, which was performed with a double stapled end to end technique. In case of ISR, the specimen is exteriorized through the anus and a manual colo-anal anastomosis was performed.

Statistical analysis

Categorical variables were reported as number of cases and percentage, while continuous variables were expressed as mean \pm (standard deviation) or median [25–75 percentile], depending on their distribution. The chi-square test and Fisher test were used to compare the distribution of categorical variables. For continuous variables, paired comparisons were made using an independent t test or Mann–Whitney test, while multiple comparisons were performed by means of an analysis of variance or Kruskal–Wallis test. The Bonferroni and Mann-Whitney test with Bonferroni correction were considered for post hoc test. Patient characteristics and perioperative data among Si-RobTME and Xi-RobTME subgroups identified through the CUSUM analysis were compared. Generalized linear models were used to estimate costs associated with the different surgical techniques and phases, adjusting for clinical characteristics and operative parameters. Variables with a p value <0.10 at univariate analysis were included in the multivariable analysis. A p value <0.05 was considered statistically significant. All analyses were per-

formed using R v3.0.2 (R, Vienna, Austria), Stata version 12 (StataCorp, College Station, TX, USA) and SPSS (Statistical Production and Service Solution for Windows, SPSS Inc., Chicago, IL, USA).

RESULTS

The evaluation of the Si-RobTME and Xi-RobTME groups according to p-g-curve and based on the CUSUM analysis identified two homogeneous phases in both groups: Si1 and Xi1: cases 1–19, corresponding to the initial p-g-curve; Si2 and Xi2: cases 20–40 characterised by stabilization of OT (Figure 1).

Demographic characteristics and preoperative condition of the two groups are summarized in Table 1. No significant differences in clinical features between the two groups were identified. Perioperative and pathological data are summarized in Table 2. There was no difference in the surgical procedures performed between the two groups. Mean overall operative time (OT) and mean docking time were significantly shorter in the Xi-RobTME: 283 ± 49 min vs. 311 ± 58 min in the Si-RobTME group ($p=0.025$), with a mean difference of -27.5 min (95% CI 3.6 - 51.4), and 16.8 ± 3.5 min in the Xi-RobTME group vs. 22.0 ± 2.5 min in the Si-RobTME group ($p<0.01$), with the mean difference of -5.3 min (95% CI 3.9 - 6.6), respectively. There were no conversions to conventional laparoscopy or HALS technique. The procedure was converted to a traditional open approach in one case in the Si-RobTME group for visceral obesity and in two cases in the Xi-RobTME group for the difficulty in identifying planes due to constant oozing from dissection planes because of a coagulopathy in a patient with liver cirrhosis, and for diffuses adhesions due to previous surgery and for anaesthesiologic problems in the second patient. No differences were reported between the two groups with respect to pathological findings. The mean distal resection margin was 2.3 ± 1.4 cm in the Si-RobTME group versus 2.4 ± 1.2 cm in the Xi-RobTME group ($p=0.73$). A mean of 17 ± 7 lymph nodes per patient were removed in the Si-RobTME group versus 19 ± 8.0 in the Xi-RobTME group ($p=0.20$). No patients had involvement of circumferential resection margins (≤ 1 mm) and the quality of the mesorectum, according to Quirke's criteria [24] was 'complete' in all cases.

Post-operative data are summarized in Table 3. Median post-operative length of stay was significantly shorter in the Xi-RobTME group (7 days vs. 9.5 days, $p<0.001$). Post-operative complications occurred in 14 cases in the Si-RobTME group (grade I in 2, grade II in 10, and grade III in 2 on to the Clavien-Dindo Classification) versus 10 cases in the Xi-RobTME group (grade I in 5, grade II in 4, and grade III in 1 according to the Clavien-Dindo Classification) ($p=0.33$). Four patients in the Si-RobTME group vs. one patient in the Xi-RobTME group ($p=0.36$) experienced transient small bowel obstruction, which resolved with insertion of a 24-F Foley catheter in the ileostomy. One patient in the Xi-RobTME group underwent laparoscopic exploration with closure of the ileostomy on 17th postoperative day for acute

abdomen due to perforation of the afferent loop of the ileostomy ($p=0.99$). No in-hospital mortality was noted in the two groups.

The comparison of patient characteristics and perioperative data by the CUSUM learning phases are summarized in Table 4. There were no differences in patient characteristics in the learning phases. The hybrid approach was used in a higher percentage of patients in the Si1 phase than Si2 phase (11 vs. 7 cases) as distinct from no patients in the Xi1 and Xi2 phases ($p<0.01$).

The comparison of costs incurred by the Si-RobTME and Xi-RobTME groups is summarized in Table 5. Overall median variable costs associated with Xi-RobTME group were significantly lower than with Si-RobTME group: 7,687€ versus 10,242 €, respectively ($p<0.001$). Both costs related to the hospital stay, the cost of consumables and personnel were significantly lower in the Xi-RobTME ($p<0.001$, $p<0.001$ and $p=0.021$, respectively).

When comparing by robotic phases, OVC were lower in Xi1 and Xi2 compared to both Si1 ($p<0.001$ and $p=0.002$) and Si2 ($p<0.001$ and $p=0.009$). A statistically significant change in OT by phase of robotic experience was detected ($p <0.001$). Mean OT was significantly lower in Si2 vs. Si1 ($p=0.003$), Xi2 vs. Xi1 ($p=0.009$) also Xi2 vs. Si1 ($p<0.001$) which reflected in PC. The reduction of OT with an increase of robotic experience is accompanied with reduction of PC ($p<0.001$), but statistically significant differences were present only when comparing the experienced vs. the initial phase in both Si ($p=0.003$) and Xi ($p=0.009$). A statistically significant reduction in CC by system and robotic phase was detected ($p<0.001$), and the CC of the Xi2 phase were significantly lower than both Si1 and Si2 phase ($p<0.001$). Moreover, HC showed a statistically significant difference by both system and robotic phase ($p=0.001$) with lower cost in the Xi1 phase compared to both Si1 and Si2 ($p<0.001$ for both). Only borderline significant difference was found in HC when comparing the Xi2 phase vs. the Si2 phase (3,302€ vs. 4,717€, $p=0.046$).

At multivariable analysis, when adjusting for potential confounding variables, OVC remained significantly lower in Xi2 as compared to both Si1 and Si2 ($p=0.002$ and $p=0.030$, respectively), CC of Xi2 was significantly lower than both phases of Si ($p<0.001$) while PC were lower in Xi2 compared to Si1 and Xi1 ($p<0.001$ and $p=0.005$ respectively) (Table 6).

DISCUSSION

The use of da Vinci robot has spread rapidly in colorectal cancer surgery even if its alleged reported advantages over the direct manual laparoscopic approach, including lower conversion rate, shorter p-g-curve and improved functional outcomes (1, 3, 6-8, 18], have not been fully confirmed by the recently published randomized clinical trial, and meta-analyses [9-12]. The results of these studies indicate that selected patients, such as obese, men, those with cancer of the lower rectum, and patients operated after receiving preoperative chemoradiotherapy, are those for whom there is high-level evidence of superiority

of RAS over direct manual laparoscopic surgery [25-30]. However, the downside of the RAS technique, which remains a critical issue preventing its widespread uptake, relates to its high capital, amortization, recurrent costs and longer operating time. In the da Vinci Si, the longer operative time is related to limitations intrinsic to this version, including its complicated setup, limited ability to reach all the abdominal quadrants without rearrangement of robotic arms, re-docking and/or repositioning of the surgical cart [18]. The increased costs associated with RAS result not only because of high purchase and maintenance costs of the robot, but also because of high costs of surgical consumables, and the longer operating room times confirmed by several publications [18, 31, 32]. However, one must stress that all the publications refer to experience based on use of the early versions of the da Vinci System including the penultimate one, the Si. The new da Vinci Xi with its innovations, has overcome some of the limitations of the preceding platforms. Indeed, preliminary studies have indicated that the use of the new da Vinci Xi by its technological improvements has the distinct potential to reduce significantly the operating time. Aside from having a shorter docking time, the Xi is more able to cope with multi-quadrant surgery, thereby increasing the full robotic execution of rectal cancer operations, when compared with the da Vinci Si [13, 15-18, 23]. Because these considerations, may translate to reduced costs, we considered the possibility that current reported literature may be exaggerating the increased costs associated with RAS by the da Vinci platform. This consideration has promoted the design and conduct of this cost analysis of a single surgeon's first consecutive 40 robotic rectal resections with the da Vinci Si with the first consecutive 40 consecutive robotic rectal resections performed with the da Vinci Xi. In the process, the study also compared the phases of p-g-curve of the robotic experience by the two systems. The CUSUM method was used to analyse the p-g-curve based on the first 90 cases of robot-assisted rectal cancer resection performed using both the da Vinci platforms. CUSUM p-g-curves are used as indicators to detect the acquisition of clinical proficiency in the execution of operations. This method of analysis allowed us to obtain two subgroups that reflect homogeneous phases: the first phase of learning and a second phase of stabilization of the times. Indeed, given that CUSUM is recognised as a method that provides quality control, it is well suited to analyse changes in parameters characterizing productive processes and hence identify "phases" within the process. For that reason, since our objective was to match phases of the process (not patients as it is common in clinical studies), this method was used to identify (and match) phases of the learning process. It has several advantages, including independence on sample size, effectiveness in detecting small changes, its ability to allow for a continuous analysis in time and rapid evaluation of data [23]. Many authors agree that the p-g-curve embraces different phases in which surgeons first gain robotic skills and then, with increasing familiarity with the new technique and new technology, the surgeon is able to decrease in OT and hospital costs over time [23, 33-35]. In changing from da Vinci Si to da Vinci Xi, the surgeon must deal with the novel aspects of the new platform such as different trocar placements, robotic cart position, new functions (pointing,

targeting, camera hopping, etc.), new docking system and robotic arms regulation [18]; even if the surgeon is already expert in both laparoscopic and robotic laparoscopic rectal resections. We have reported previously that after the first two cases of rectal resection performed with the da Vinci Xi, in which the 'classic' Universal Port Placement Guidelines provided by Intuitive Surgical for 'left lower' abdominal procedures was used, a modification of the trocar placement was used [16], which facilitates the approach to the transverse colon and splenic flexure by increasing the manipulation space, without causing difficulties during the pelvic phase, only possible by the intrinsic flexibility of the da Vinci Xi [18]. With further experience, we changed our surgical technique of robotic rectal resection with da Vinci Xi further by replacing the double targeting technique during the first phase, consisting of initial targeting the mesenteric vein isolation and splenic flexure mobilization, followed by the second targeting the pelvis, to a single targeting technique modifying only the FLEX of the robotic arm for the two phases of the operation with a further reduction of the operating time. All these modifications are features of a proficiency-gain phase for the first Xi cases.

Our costs analysis revealed a significant decrease of OVC with surgeon's experience. The impact on reduction of costs with surgeon's experience is in accordance with data reported in our previous costs analysis comparing laparoscopic rectal resection with robotic rectal resection performed with the da Vinci Si [23]. Although the documented cost reduction is likely to be multifactorial, the optimization of instrument use and reduction of OT are two major contributors [23]. A further decrease of costs is clearly related to the shift from the Si to the Xi technology and is characterised by the significant reduction in OT, PC and CC associated with use of the new da Vinci Xi. However, the significant reduction of HS with the da Vinci Xi vs. Si-RobTME must be treated with caution, as the data on HS is subject to bias. Thus, it can be explained by the difference in post-operative complications in the two groups or could be secondary to an enhanced recovery protocol in Xi-RobTME group. Additionally, because the Si-RobTME group included patients treated during our early experience with the robotic surgery, a more cautious policy may have been used for discharging patients from hospital [36].

In contrast, we believe that the reduction of OT and the improved ability to perform the procedure by a fully robotic approach offered by the da Vinci Xi are the two main factors influencing the reduction of costs. Indeed, the technological improvements offered by the da Vinci Xi, i.e., increased flexibility and range of motion of the cart and arms, as well as the ability to obtain the excellent exposure of the operative field without repositioning the patient have contributed to shorter operative and console times and the increased rate of fully robotic resections, well documented in the literature [15-17, 19, 20]. The reduction of the OT has influenced in turn reduction in PC because of a lower Operative Room (OR) hours. Our observation is in line with those recently report by Patel et al. in urology, that revealed in a comparative study with the da Vinci Si, that the da Vinci Xi robotic nephroureterectomy reduced overall HC due to the reduction of anaesthesia and OR cost [37]. The significant reduction of the CC, was mainly due to

the higher number of full robotic operations achieved with the da Vinci Xi, because it avoids the use of laparoscopic instruments and devices for the laparoscopic phase used in the hybrid technique.

The main limitations of the present study are its retrospective nature and the small sample size, which preclude definitive conclusions. In addition, as the study is based on experience of a single surgeon, its more general application to robotic-assisted rectal cancer surgery is limited without further collaborative studies. A further limitation imposed by the study design was the exclusion of capital costs and amortisation from the analysis. Hence, we acknowledge that their inclusion would be necessary for a complete assessment of overall costs.

However, the present study, the first to compare costs incurred using the new da Vinci Xi with its predecessor has produced cost differences, some of which are significant, but obviously further larger structured cost analysis studies are needed to confirm the cost minimization by the da Vinci Xi.

Perhaps, the most important take home message from the present study is to highlight that the current economic evaluation on robotic assisted surgery that have provided unfavorable cost comparisons between robotic assisted surgery compared to manual direct laparoscopy surgery, have all been based on studies performed with the da Vinci Si, and further compounded by comparing expert laparoscopic with novice robotic surgeons. The use of the new robot Xi, with case series being performed by expert robotic surgeons represents a totally different proposition, requiring careful objective re-evaluation of relative costs between the two surgical approaches.

CONCLUSIONS

In conclusion, the similar p-g-curve for both groups were likely due to a 'proficiency-gain effect' related mainly to the use of a new robotic technology, and not to the surgical operation itself. In taking up the new technology, the surgeon initially becomes familiar with new trocar placements, robotic cart position, new functions (pointing, targeting, camera hopping, etc.), new docking system and robotic arms regulation. Beyond this initial familiarization stage, the study has documented a significant decrease of costs with increasing surgeon's experience, and change from the Si to the Xi da Vinci, which is characterised by shorter OT, PC, and reduction in the CC, together with enabling a higher number of full robotic operations than previously possible with the da Vinci Si. However, the important limitation of robotic TME rectal resection for cancer, and of robotic surgery in general that persists relates to the high fixed costs. Efforts to reduce these are essential for both long-term financial sustainability of robotic surgery and increased uptake of RAS needed to improve the outcome of patients undergoing curative surgical excision of solid cancers resulting from technical advantages offered by the robotic platforms.

Author Disclosures

Prof Luca Morelli, Dr Gregorio Di Franco, Dr Valentina Lorenzoni, Dr Simone Guadagni, Dr Matteo Palmeri, Dr Niccolò Furbetta, Dr Desirée Gianardi, Dr Mattero Bianchini, Dr Giovanni Caprili, Prof Franco Mosca, Prof Giuseppe Turchetti, Prof Alfred Cuschieri have no conflicts of interest or financial ties to disclose.

References

1. Luca F, Valvo M, Ghezzi TL, Zuccaro M, Cenciarelli S, Trovato C, Sonzogni A, Biffi R (2013) Impact of robotic surgery on sexual and urinary functions after fully robotic nerve-sparing total mesorectal excision for rectal cancer. *Ann Surg* 257:672–8. doi: 10.1097/SLA.0b013e318269d03b
2. D'Annibale A, Morpurgo E, Fiscon V, Trevisan P, Sovernigo G, Orsini C, Guidolin D (2004) Robotic and laparoscopic surgery for treatment of colorectal diseases. *Dis Colon Rectum* 47:2162–8. doi: 10.1007/s10350-004-0711-z
3. D'Annibale A, Pernazza G, Monsellato I, Pende V, Lucandri G, Mazzocchi P, Alfano G (2013) Total mesorectal excision: a comparison of oncological and functional outcomes between robotic and laparoscopic surgery for rectal cancer. *Surg Endosc* 27:1887–1895. doi: 10.1007/s00464-012-2731-4
4. Morelli L, Ceccarelli C, Di Franco G, Guadagni S, Palmeri M, Caprili G, D'Isidoro C, Marciano E, Pollina L, Campani D, Massimetti G, Di Candio G, Mosca F (2016) Sexual and urinary functions after robot-assisted versus pure laparoscopic total mesorectal excision for rectal cancer. *Int J Colorectal Dis* 31:913–5. doi: 10.1007/s00384-015-2301-z
5. Delacroix SE, Winters JC (2010) Voiding dysfunction after pelvic colorectal surgery. *Clin Colon Rectal Surg* 23:119–27. doi: 10.1055/s-0030-1254299
6. Young M, Pigazzi A (2014) Total Mesorectal Excision: Open, Laparoscopic or Robotic. In: *Recent Results Cancer Res.* pp 47–55
7. Bianchi PP, Ceriani C, Locatelli A, Spinoglio G, Zampino MG, Sonzogni A, Crosta C, Andreoni B (2010) Robotic versus laparoscopic total mesorectal excision for rectal cancer: a comparative analysis of oncological safety and short-term outcomes. *Surg Endosc* 24:2888–2894. doi: 10.1007/s00464-010-1134-7
8. Baek J-H, Pastor C, Pigazzi A (2011) Robotic and laparoscopic total mesorectal excision for rectal cancer: a case-matched study. *Surg Endosc* 25:521–5. doi: 10.1007/s00464-010-1204-x
9. Jayne D, Pigazzi A, Marshall H, Croft J, Corrigan N, Copeland J, Quirke P, West N, Rautio T, Thomassen N, Tilney H, Gudgeon M, Bianchi P Pietro, Edlin R, Hulme C, Brown J (2017) Effect of Robotic-Assisted vs Conventional Laparoscopic Surgery on Risk of Conversion to Open Laparotomy Among Patients Undergoing Resection for Rectal Cancer: The ROLARR Randomized Clinical Trial. *JAMA* 318:1569. doi: 10.1001/jama.2017.7219
10. Wang Y, Zhao G-H, Yang H, Lin J (2016) A Pooled Analysis of Robotic Versus Laparoscopic Surgery for Total Mesorectal Excision for Rectal Cancer. *Surg Laparosc Endosc Percutan Tech* 26:259–264. doi: 10.1097/SLE.0000000000000263
11. Li X, Wang T, Yao L, Hu L, Jin P, Guo T, Yang K (2017) The safety and effectiveness of robot-

assisted versus laparoscopic TME in patients with rectal cancer. *Medicine (Baltimore)* 96:e7585. doi: 10.1097/MD.00000000000007585

12. Cheng CL, Rezac C (2018) The role of robotics in colorectal surgery. *BMJ* 360;j5304.
13. Hagen ME, Jung MK, Ris F, Fakhro J, Buchs NC, Buehler L, Morel P (2016) Early clinical experience with the da Vinci Xi Surgical System in general surgery. *J Robot Surg*. doi: 10.1007/s11701-016-0662-0
14. Protyniak B, Jorden J, Farmer R (2017) Multi-quadrant robotic colorectal surgery: the da Vinci Xi vs Si comparison. *J Robot Surg*. doi: 10.1007/s11701-017-0689-x
15. Ozben V, Cengiz TB, Atasoy D, Bayraktar O, Aghayeva A, Erguner I, Baca B, Hamzaoglu I, Karahasanoglu T (2016) Is da Vinci Xi Better than da Vinci Si in Robotic Rectal Cancer Surgery? Comparison of the 2 Generations of da Vinci Systems. *Surg Laparosc Endosc Percutan Tech* 26:417–423. doi: 10.1097/SLE.0000000000000320
16. Morelli L, Guadagni S, Di Franco G, Palmeri M, Caprili G, D'Isidoro C, Pisano R, Moglia A, Ferrari V, Di Candio G, Mosca F (2015) Use of the new Da Vinci Xi during robotic rectal resection for cancer: technical considerations and early experience. *Int J Colorectal Dis* 30:1281–1283. doi: 10.1007/s00384-015-2350-3
17. Morelli L, Guadagni S, Di Franco G, Palmeri M, Caprili G, D'Isidoro C, Cobuccio L, Marciano E, Di Candio G, Mosca F (2017) Use of the new da Vinci Xi® during robotic rectal resection for cancer: a pilot matched-case comparison with the da Vinci Si®. *Int J Med Robot Comput Assist Surg* 13:e1728. doi: 10.1002/rcs.1728
18. Morelli L, Di Franco G, Guadagni S, Rossi L, Palmeri M, Furbetta N, Gianardi D, Bianchini M, Caprili G, D'Isidoro C, Mosca F, Moglia A, Cuschieri A (2018) Robot-assisted total mesorectal excision for rectal cancer: case-matched comparison of short-term surgical and functional outcomes between the da Vinci Xi and Si. *Surg Endosc* 32:589–600. doi: 10.1007/s00464-017-5708-5
19. Morelli L, Palmeri M, Guadagni S, Di Franco G, Moglia A, Ferrari V, Cariello C, Buccianti P, Simoncini T, Zirafa C, Melfi F, Di Candio G, Mosca F (2016) Use of a new integrated table motion for the da Vinci Xi in colorectal surgery. *Int J Colorectal Dis* 31:1671–1673. doi: 10.1007/s00384-016-2609-3
20. Palmeri M, Gianardi D, Guadagni S, Di Franco G, Bastiani L, Furbetta N, Simoncini T, Zirafa C, Melfi F, Buccianti P, Moglia A, Cuschieri A, Mosca F, Morelli L (2018) Robotic Colorectal Resection With and Without the Use of the New Da Vinci Table Motion: A Case-Matched Study. *Surg Innov* 155335061876554. doi: 10.1177/1553350618765540
21. Morelli L, Palmeri M, Simoncini T, Cela V, Perutelli A, Selli C, Buccianti P, Francesca F, Cecchi M, Zirafa C, Bastiani L, Cuschieri A, Melfi F (2018) A prospective, single-arm study on the use of

- the da Vinci® Table Motion with the Trumpf TS7000dV operating table. *Surg Endosc*. doi: 10.1007/s00464-018-6161-9
22. Dindo D, Demartines N, Clavien P-A (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 240:205–13.
 23. Morelli L, Guadagni S, Lorenzoni V, Di Franco G, Cobuccio L, Palmeri M, Caprili G, D’Isidoro C, Moglia A, Ferrari V, Di Candio G, Mosca F, Turchetti G (2016) Robot-assisted versus laparoscopic rectal resection for cancer in a single surgeon’s experience: a cost analysis covering the initial 50 robotic cases with the da Vinci Si. *Int J Colorectal Dis* 31:1639–48. doi: 10.1007/s00384-016-2631-5
 24. Hellan M, Anderson C, Ellenhorn JDI, Paz B, Pigazzi A (2007) Short-term outcomes after robotic-assisted total mesorectal excision for rectal cancer. *Ann Surg Oncol* 14:3168–73. doi: 10.1245/s10434-007-9544-z
 25. Shiomi A, Kinugasa Y, Yamaguchi T, Kagawa H, Yamakawa Y (2016) Robot-assisted versus laparoscopic surgery for lower rectal cancer: the impact of visceral obesity on surgical outcomes. *Int J Colorectal Dis* 31:1701–10. doi: 10.1007/s00384-016-2653-z
 26. Ackerman SJ, Daniel S, Baik R, Liu E, Mehendale S, Tackett S, Hellan M (2018) Comparison of complication and conversion rates between robotic-assisted and laparoscopic rectal resection for rectal cancer: which patients and providers could benefit most from robotic-assisted surgery? *J Med Econ* 21:254–261. doi: 10.1080/13696998.2017.1396994
 27. Panteleimonitis S, Pickering O, Abbas H, Harper M, Kandala N, Figueiredo N, Qureshi T, Parvaiz A (2018) Robotic rectal cancer surgery in obese patients may lead to better short-term outcomes when compared to laparoscopy: a comparative propensity scored match study. *Int J Colorectal Dis* 33:1079–1086. doi: 10.1007/s00384-018-3030-x
 28. Esen E, Aytac E, Ağcaoğlu O, Zenger S, Balik E, Baca B, Hamzaoğlu İ, Karahasanoğlu T, Buğra D (2018) Totally Robotic Versus Totally Laparoscopic Surgery for Rectal Cancer. *Surg Laparosc Endosc Percutan Tech* 28:1. doi: 10.1097/SLE.0000000000000552
 29. Ramos ER, Jiang Y, Hachem R, Kassis C, Kontoyiannis DP, Raad I (2011) Outcome Analysis of Invasive Aspergillosis in Hematologic Malignancy and Hematopoietic Stem Cell Transplant Patients: The Role of Novel Antimold Azoles. *Oncologist* 16:1049–1060. doi: 10.1634/theoncologist.2010-0290
 30. Nozawa H, Watanabe T (2017) Robotic surgery for rectal cancer. *Asian J Endosc Surg* 10:364–371. doi: 10.1111/ases.12427
 31. Ramji KM, Cleghorn MC, Josse JM, MacNeill A, O’Brien C, Urbach D, Quereshy FA (2016) Comparison of clinical and economic outcomes between robotic, laparoscopic, and open rectal

- cancer surgery: early experience at a tertiary care center. *Surg Endosc* 30:1337–43. doi: 10.1007/s00464-015-4390-8
32. Baek S-J, Kim S-H, Cho J-S, Shin J-W, Kim J (2012) Robotic versus conventional laparoscopic surgery for rectal cancer: a cost analysis from a single institute in Korea. *World J Surg* 36:2722–9. doi: 10.1007/s00268-012-1728-4
 33. Park EJ, Kim CW, Cho MS, Baik SH, Kim DW, Min BS, Lee KY, Kim NK (2014) Multidimensional analyses of the learning curve of robotic low anterior resection for rectal cancer: 3-phase learning process comparison. *Surg Endosc* 28:2821–31. doi: 10.1007/s00464-014-3569-8
 34. Jiménez-Rodríguez RM, Rubio-Dorado-Manzanares M, Díaz-Pavón JM, Reyes-Díaz ML, Vazquez-Monchul JM, Garcia-Cabrera AM, Padillo J, De la Portilla F (2016) Learning curve in robotic rectal cancer surgery: current state of affairs. *Int J Colorectal Dis* 31:1807–1815. doi: 10.1007/s00384-016-2660-0
 35. Bokhari MB, Patel CB, Ramos-Valadez DI, Ragupathi M, Haas EM (2011) Learning curve for robotic-assisted laparoscopic colorectal surgery. *Surg Endosc* 25:855–860. doi: 10.1007/s00464-010-1281-x
 36. Giulianotti PC, Coratti A, Angelini M, Sbrana F, Cecconi S, Balestracci T, Caravaglios G (2003) Robotics in general surgery: personal experience in a large community hospital. *Arch Surg* 138:777–84. doi: 10.1001/archsurg.138.7.777
 37. Patel MN, Hemal A (2017) Does advancing technology improve outcomes? Comparison of the da Vinci Standard/S/Si to the Xi robotic platforms during robotic nephroureterectomy. *J Endourol* end.2017.0477. doi: 10.1089/end.2017.0477.

Figure Legend

Figure 1 – RobTME operative time (OT): CUSUM chart for OT (Panel a) for the Si-RobTME group (left) and the Xi-RobTME group (right); Plot of OT against case number (Panel b) for the Si-RobTME group (left) and the Xi-RobTME group (right).